Gyongyi Szabo, MD
San Francisco— Combination therapy with zinc and the recombinant human interleukin-1 (IL-1) receptor antagonist anakinra may provide both short- and long-term survival benefits in patients with severe alcoholic hepatitis, new research shows.
“Patients with severe alcoholic hepatitis have a 90-day mortality rate that’s often worse than newly diagnosed stage 4 cancers, yet there are very few therapeutic options for this patient population,” said Gyongyi